Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. PACAP38 and PAC receptor blockade: a new target for headache?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pregnancy Loss and Cancer Risk: A Nationwide Observational Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sphenopalatine ganglion block for treatment of post-dural puncture headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for surgical intervention of early medical abortion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH)
Vis graf over relationer

We systematically reviewed data about the effect of exogenous estrogens and progestogens on the course of migraine during reproductive age. Thereafter a consensus procedure among international experts was undertaken to develop statements to support clinical decision making, in terms of possible effects on migraine course of exogenous estrogens and progestogens and on possible treatment of headache associated with the use or with the withdrawal of hormones. Overall, quality of current evidence is low. Recommendations are provided for all the compounds with available evidence including the conventional 21/7 combined hormonal contraception, the desogestrel only oral pill, combined oral contraceptives with shortened pill-free interval, combined oral contraceptives with estradiol supplementation during the pill-free interval, extended regimen of combined hormonal contraceptive with pill or patch, combined hormonal contraceptive vaginal ring, transdermal estradiol supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous estrogen implant with cyclical oral progestogen. As the quality of available data is poor, further research is needed on this topic to improve the knowledge about the use of estrogens and progestogens in women with migraine. There is a need for better management of headaches related to the use of hormones or their withdrawal.

OriginalsprogEngelsk
TidsskriftJournal of Headache and Pain
Vol/bind19
Udgave nummer1
Sider (fra-til)76
ISSN1129-2369
DOI
StatusUdgivet - 31 aug. 2018

ID: 55200911